Haemonetics Corporation (NYSE:HAE) Receives Average Rating of “Moderate Buy” from Analysts

Haemonetics Corporation (NYSE:HAE) has received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $79.70.

A number of brokerages have commented on HAE. Needham & Company LLC raised their price target on shares of Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 target price (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. BTIG Research upped their price target on Haemonetics from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings cut Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Finally, Barrington Research boosted their target price on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, November 7th.

Haemonetics Stock Down 0.6%

HAE opened at $73.48 on Tuesday. The company has a market capitalization of $3.44 billion, a P/E ratio of 22.47, a P/E/G ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.72 and a quick ratio of 1.04. The firm’s fifty day moving average price is $53.39 and its two-hundred day moving average price is $62.48. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $91.43.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same period last year, the firm earned $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Institutional Trading of Haemonetics

Several hedge funds have recently modified their holdings of HAE. Parkside Financial Bank & Trust boosted its holdings in shares of Haemonetics by 11.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after acquiring an additional 152 shares in the last quarter. GAMMA Investing LLC raised its position in Haemonetics by 59.4% in the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 165 shares during the last quarter. Quarry LP boosted its stake in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Haemonetics by 1.4% during the first quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier’s stock worth $896,000 after purchasing an additional 200 shares during the last quarter. Finally, Verdence Capital Advisors LLC increased its stake in shares of Haemonetics by 3.6% in the second quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock valued at $464,000 after buying an additional 214 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.